COHERUS BIOSCIENCES ($CHRS) posted quarterly earnings results for Q4 2025 on Monday, March 9th. The company reported earnings of -$0.34 per share, beating estimates of -$0.36 by $0.02. The company also reported revenue of $12,750,000, missing estimates of $14,223,390 by $-1,473,390.
Stock price change since market close: -6.15%
You can see Quiver Quantitative's $CHRS stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
COHERUS BIOSCIENCES Hedge Fund Activity
We have seen 60 institutional investors add shares of COHERUS BIOSCIENCES stock to their portfolio, and 59 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TANG CAPITAL MANAGEMENT LLC removed 2,372,853 shares (-46.6%) from their portfolio in Q4 2025, for an estimated $3,369,451
- MACQUARIE GROUP LTD removed 899,999 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $1,277,998
- RUBRIC CAPITAL MANAGEMENT LP removed 867,800 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,423,192
- TEJARA CAPITAL LTD removed 698,770 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,145,982
- MILLENNIUM MANAGEMENT LLC added 660,451 shares (+inf%) to their portfolio in Q4 2025, for an estimated $937,840
- GSA CAPITAL PARTNERS LLP added 477,481 shares (+inf%) to their portfolio in Q4 2025, for an estimated $678,023
- TWO SIGMA INVESTMENTS, LP added 468,163 shares (+1310.9%) to their portfolio in Q4 2025, for an estimated $664,791
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
